• Explore /
  • Poster
  • / A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.

A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.

Abstract Poster

Authors

Andrea Apolo

Andrea B. Apolo

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Andrea B. Apolo , Amir Mortazavi , Mark N. Stein , Nicole N. Davarpanah , Rosa Maria Nadal , Howard L. Parnes , Yangmin M. Ning , Deneise C Francis , Lisa M Cordes , Marilise Anne Berniger , Seth M. Steinberg , Piyush K. Agarwal , Mohammadhadi H. Bagheri , Swati Nanda , Paul Monk III, Tiffany Lancaster , Tina Moore , Rene Costello , Donald P. Bottaro , Sumanta K. Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02496208

Citation

J Clin Oncol 35, 2017 (suppl; abstr 4562)

DOI

10.1200/JCO.2017.35.15_suppl.4562

Abstract #

4562

Poster Bd #

240

Abstract Disclosures

Similar Posters

First Author: Andrea B. Apolo

First Author: Rosa Nadal

First Author: Rosa Maria Nadal

First Author: Bradley Alexander McGregor